ADCT

ADC Therapeutics SA (ADCT)

About ADC Therapeutics SA (ADCT)

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Details

Daily high

$3.09

Daily low

$2.96

Price at open

$3.01

52 Week High

$6.04

52 Week Low

$0.36

Market cap

294.9M

Dividend yield

0.00%

Volume

205,510

Avg. volume

361,388

P/E ratio

-1.19

ADC Therapeutics SA News